Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott IVD manufacturing facility reinspection by FDA expected in next few weeks.

This article was originally published in The Gray Sheet

Executive Summary

ABBOTT REINSPECTION BY FDA TO ADDRESS IVD MANUFACTURING DEFICIENCIES is expected to take place in the next few weeks, according to the firm. The reinspection of the company's Abbott Park, Illinois in vitro diagnostic production facilities is intended to verify that Abbott has completed corrective actions taken in response to violations of good manufacturing practices found by FDA during audits in 1993 and 1994. The upcoming inspection will be conducted jointly by FDA's Chicago District Office and centers for devices and biologics.

You may also be interested in...



Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress

Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel